Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease

**
https://doi.org/10.1016/S0002-9343(96)00009-5Get rights and content

Objective

To determine whether low-dose aspirin or warfarin induces fecal occult blood loss.

Patients and methods

A prospective, crossover study, of 100 participants over 40 years of age in 1 of 3 groups, taking: (1) no aspirin or warfarin, (2) daily aspirin (either 81 or 325 mg), or (3) warfarin, but no aspirin. Stool samples were collected and analyzed for the presence of occult blood using HemoQuant and Hemoccult II. After collection of baseline samples, patients initially taking no aspirin (group 1) were asked to take regular aspirin (325 mg daily) for 2 months. Patients initially taking aspirin 81 mg daily (group 2) were switched to 325 mg daily for 2 months, and vice versa.

Results

Patients taking no aspirin had mean fecal blood of 0.68 ± 0.05 mg hemoglobin/g stool, which increased to 1.41 ± 0.36 mg/g after taking 325 mg of aspirin daily (P = 0.02). In contrast, patients in group 2, taking 81 mg and 325 mg of aspirin, had mean fecal blood of 0.82 ± 0.08 mg/g (P = 0.57) and 1.04 ± 0.23 mg/g (P = 0.13), respectively (comparisons with patients taking no aspirin). The mean blood loss in patients taking warfarin was 0.51 ± 0.04 mg/g (P = 0.55), and fecal blood was not related to the degree of anticoagulation. There was no increase over normal in the rate of Hemoccult II-positive stool tests with aspirin or warfarin therapy.

Conclusion

Aspirin, but not warfarin, caused a small but clinically insignificant increase in occult fecal blood. The small blood loss in patients taking aspirin or warfarin is unlikely to interfere with fecal occult blood tests. Therefore, positive fecal occult blood tests, in patients taking either low-dose aspirin or warfarin, should be managed in the same fashion as patients not taking these medications.

References (19)

There are more references available in the full text version of this article.

Cited by (54)

  • Effect of aspirin on the pharmacokinetics and absorption of panax notoginseng saponins

    2018, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
  • Gastrointestinal malignancies and cardiovascular diseases-Non-negligible comorbidity in an era of multi-antithrombotic drug use

    2011, Journal of Cardiology
    Citation Excerpt :

    In that study, however, healthy volunteers underwent only 30 days of treatment with daily aspirin or placebo. In a prospective, cross-over study, in which 100 participants over 40 years of age were enrolled, the same group reported that aspirin, but not warfarin, caused a small but clinically insignificant increase in occult fecal blood; therefore, patients taking either low-dose aspirin or warfarin can be managed in the same fashion as patients not taking these medications [32]. Again it should be noted that, essentially healthy subjects who were not on antithrombotic drugs on a regular basis were enrolled in that study.

  • In Reply

    2007, American Journal of Kidney Diseases
View all citing articles on Scopus
View full text